



## Corrigendum

## Corrigendum to “Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study” [Heliyon 8 (6) (2022) e09538]



Lei Zhao<sup>a,b</sup>, Nijia Chang<sup>c,1</sup>, Lei Shi<sup>b</sup>, Fengyi Li<sup>b</sup>, Fanglin Meng<sup>b</sup>, Xiaohui Xie<sup>b</sup>, Zhe Xu<sup>b,\*\*</sup>, Fusheng Wang<sup>b,\*</sup>

<sup>a</sup> Medical school of Chinese PLA, Chinese PLA General Hospital, Beijing, 100853, China

<sup>b</sup> Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, 100039, China

<sup>c</sup> The Second Medical Center of PLA General Hospital, Beijing, 100039, China

In the original published version of this article one of the authors names was misspelt. The correct spelling of Nijia Chang is to **Nijia Chang**. The correct spelling of the name of the author can also be found below. The authors apologize for the errors. Both the HTML and PDF versions of the article have been updated to correct the errors.

Name: **Nijia Chang**

Affiliation: *The Second Medical Center of PLA General Hospital, Beijing, 100039, China*

DOI of original article: <https://doi.org/10.1016/j.heliyon.2022.e09538>.

\* Corresponding author.

\*\* Corresponding author.

E-mail addresses: [xuzhe302@139.com](mailto:xuzhe302@139.com) (Z. Xu), [Fswang302@163.com](mailto:Fswang302@163.com) (F. Wang).

<sup>1</sup> These authors contributed to the work equally and should be regarded as co-first author.

<https://doi.org/10.1016/j.heliyon.2022.e11404>

Received 18 October 2022; Accepted 18 October 2022

2405-8440/© 2022 Published by Elsevier Ltd.